RxDoctor Payments Data

Stephen Amann, MD

Gastroenterology · Tupelo, MSNPI 1063471761

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 64.6% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $6,559 and has fallen 92.7% since, to $481 in 2025.

$12,520in general payments, 2019–2025

Across 297 payments — averaging $42.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$8K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$422
  • Takeda Pharmaceuticals U.S.A., Inc.$329
  • Gilead$256
  • Johnson & Johnson$241
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$6,12549%
  • Travel & lodging$1,61613%
  • Food & beverage$4,77938%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,520 in reported general payments places this provider in the 85th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$260,142
Medicare patients
769
Services billed
5,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$76,264
CreonLipase/Protease/Amylase13$63,514
ZenpepLipase/Protease/Amylase21$54,530
XifaxanRifaximin11$32,922
LinzessLinaclotide55$27,511
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates207$13,658
MovantikNaloxegol Oxalate11$4,524
Ursodiol46$3,582
Mesalamine21$3,306
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,241
Pantoprazole Sodium103$2,433
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$2,283
Famotidine265$2,195
Budesonide DrBudesonide14$2,152
CholestyramineCholestyramine (With Sugar)24$1,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,485$91,02568 claims
Aimmune Therapeutics, Inc.Zenpep$41$54,53021 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$422$35,20527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →